The Global Pneumonia Therapeutics Market size in 2023 is USD 2.51 billion. The market share is projected to grow at a CAGR of 8.10% and reach USD 4.68 billion by 2031.
Global Pneumonia Therapeutics Market - Industry Overview
The global pneumonia therapeutics market is expected to grow significantly, owing predominantly to the increasing incidence of pneumonia worldwide, with a particularly strong impact in low- and middle-income countries with less solid healthcare infrastructure. Pneumonia continues to be a prominent cause of death among vulnerable groups, particularly children under the age of five, According to WHO Pneumonia killed 740180 children under the age of 5 in 2019, accounting for 14% of all deaths of children under 5 years old, highlighting the urgent need for more effective treatments and preventive measures. Rising antibiotic resistance, particularly against common infections like Streptococcus pneumoniae, is a major driver of demand for innovative medicines such as next-generation antibiotics, improved vaccines, and supportive care methods.
Data Bridge Market Research Market Report provides details of new recent developments, market share, market trends on the basis of its segmentations and regional analysis, the impact of market players, analyses of opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make informed market decisions to achieve business growth.
Global Pneumonia Therapeutics Market Size
|
Global Pneumonia Therapeutics Report Metric Details
|
|
||
|
Report Metric
|
Details
|
||
|
Forecast Period
|
2024-2032
|
||
|
Base Year
|
2024
|
||
|
Historic Year
|
2023 (Customizable 2016-2021)
|
||
|
Measuring Unit
|
USD Billion
|
||
|
Data Pointers
|
Market value, growth rate, market segments, geographical coverage, market players, and market scenario, in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
||
The global pneumonia therapeutics market is also witnessing increased investment in research and development to combat the growing threat of multidrug-resistant strains of Streptococcus pneumonia. Furthermore, the introduction of newer vaccines, such as the Pneumococcal Conjugate Vaccine (PCV), and advancements in antiviral medications are playing a critical role in mitigating the global pneumonia therapeutics market growth. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Pneumonia Therapeutics Market is increasing at a CAGR of 8.10%. Our detailed analysis forecasts that the market is valued at USD 2.51 billion in 2023 and is expected to grow upto USD 4.68 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.
Global Pneumonia Therapeutics Market Dynamics
Global Pneumonia Therapeutics Market Growth Drivers
Increase in pneumonia Cases
The rising prevalence of pneumonia, particularly among vulnerable populations such as children under five and the elderly, is a primary driver of the global pneumonia therapeutics market. According to the World Health Organization (WHO), pneumonia causes 14% of all child fatalities under the age of five, killing roughly 740,180 children each year. Such worrisome trend emphasizes the critical need for improved treatments and prevention strategies.
Antibiotic Resistance
Centers for Disease Control and Prevention (CDC) reports that in the United States alone, about 30% of Streptococcus pneumoniae infections are resistant to one or more clinically relevant antibiotics. Antibiotic resistance, particularly in strains for instance, Streptococcus pneumoniae, is a critical challenge driving the need for new antibiotics and combination therapies in the pneumonia therapeutics market. Consequently, the urgent need to combat such resistant strains has spurred significant investment in the research and development of novel antibiotics, as well as combination therapies
Global Pneumonia Therapeutics Market growth Opportunities
Growing Clinical Trials
Growing number of on-going clinical trials for the development of drug molecules will have a major impact on the market progression. For instance, According to WHO, in 2022 global clinical trial activity remained strong despite the COVID-19 pandemic. Non-COVID trial activity increased by 8% from 2019 to 2022. The expansion of clinical research not only accelerates the development of breakthrough treatments but also stimulates investment and fosters collaboration across the healthcare sector, thereby propelling the overall growth of the pneumonia therapeutics market.
Government and healthcare initiatives
Government and healthcare initiatives, including expanded immunization programs and improved healthcare access, significantly support the growth of the global pneumonia therapeutics market. for instance, U.S. Healthy People 2030 objectives, aim to improve access to preventive and therapeutic services for pneumonia, further enhancing market growth.
Global Pneumonia Therapeutics Market Growth Challenges
High Cost of Therapy
The high cost of advanced pneumonia therapies, such as novel antibiotics and biologics, presents a significant challenge to market growth. For instance, the development of new antibiotics can cost upwards of $1.5 billion, considering the extensive research, clinical trials, and regulatory processes involved. Similarly, biologics, which include monoclonal antibodies and other specialized treatments, can have development costs exceeding $2 billion. Financial barrier's limits the ability of these regions to procure and administer advanced treatments, impacting overall pneumonia management and hindering market expansion.
Lack of technical skills.
Limited healthcare infrastructure in low- and middle-income regions severely impacts pneumonia management and market growth. For instance, According to WHO the share of health in government spending increased over the past two decades in upper-middle and high income countries, stagnated in lower-middle income countries and declined in low income countries between 2000 and 2011. Consequently, the inability to provide timely and appropriate care in lower-middle income countries not only affects patient outcomes but also hinders the overall growth of the pneumonia therapeutics market.
Global Pneumonia Therapeutics Market Growth Restraints
Regulatory and market approval hurdles
The approval process for new therapies is both rigorous and time-consuming, requiring extensive Navigating regulatory and market clearance hurdles is a major problem in the pneumonia therapeutics market, frequently resulting in delays and increased costs for novel medicines. For instance, the antibiotic Ceftaroline required a lengthy approval process from the United States Food and Drug Administration (FDA) due to rigorous evaluation of clinical trial data and manufacturing practices. Such lengthy and costly approval processes not only add to pharmaceutical companies' financial burdens, but also delay the introduction of potentially life-saving pneumonia medicines to the market, impacting patient access and overall market growth.
Global Pneumonia Therapeutics Market Scope and Trends
|
Global Pneumonia Therapeutics Market Segmentations Overview
|
|
|
Market
|
Sub-Segments
|
|
Infection Type
|
Hospital-acquired Pneumonia (HAP), Community-acquired Pneumonia (CAP), Ventilator-associated Pneumonia (VAP)
|
|
Drug Class
|
Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs
|
|
Age Group
|
Pediatric, Adult, Geriatric
|
|
Type
|
Drugs, Preventive Vaccines, Oxygen Therapy
|
|
Route of Administration
|
Oral, Parenteral, Others
|
|
End-Users
|
Hospitals, Homecare, Specialty Clinics, Others
|
|
Distribution Channel
|
Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
|
- In a recent study published in the American Society for Microbiology, researchers created a unique rabbit infection model to explore meropenem's resistance development potential and antibacterial activity. Meropenem is an antibacterial medication that is considered the current gold standard in hospital-acquired pneumonia (HAP) therapy. The work contributes to the identification of Regimen Intensification and Combination Therapy as potential mitigation strategies against the formation of multiple antimicrobial resistance (AMR) bacterial strains.
- Orchid Pharma has acquired license from the Drugs Controller General of India (DCGI) to manufacture and distribute Enmetazobactam, an innovative New Chemical Entity Active Pharmaceutical Ingredient (API). Enmetazobactam will be used to treat complicated urinary tract infections (cUTI), such as acute pyelonephritis, hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and bacteremia.
- Antiviral drugs are essential for treating pneumonia caused by viral infections such as influenza and SARS-CoV-2. For instance, newer antiviral medications such as Paxlovid and Molnupiravir have been developed to combat SARS-CoV-2 and are being refined to enhance their efficacy against evolving variants.
Global Pneumonia Therapeutics Market Regional Analysis – Market Trends
|
Global Pneumonia Therapeutics Market Regional Overview
|
|
|
|
Region
|
Countries
|
|
|
Europe
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe
|
|
|
APAC
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
|
North America
|
U.S., Canada, and Mexico
|
|
|
MEA
|
Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East, and Africa
|
|
|
South America
|
Brazil, Argentina, and Rest of South America
|
|
Key Insights
- North America dominates the market due to its advanced healthcare systems and high levels of public awareness about pneumonia prevention and treatment. The United States, with its well-established healthcare infrastructure and significant investment in research and development, leads in the adoption of new pneumonia therapies.
- Asia-Pacific is predicted to rise the fastest due to rising healthcare spending, increased awareness, and improved access to pneumonia treatments. Countries such as China and India are investing in healthcare facilities and vaccination programs to combat the high prevalence of pneumonia, particularly among youngsters. The expanding middle class and improved healthcare services in the region are significant drivers of market expansion.
- Middle Eastern and African countries face low healthcare resources and infrastructure, which has an impact on pneumonia management. Despite these obstacles, there is a growing emphasis on improving healthcare systems and boosting access to vaccines and treatments, fueled by international assistance and government initiatives.
- Europe has a significant share of the pneumonia therapeutics market due to its strong healthcare systems and widespread availability of innovative therapies. The European Union's emphasis on improving public health through preventive measures including comprehensive immunization programs and excellent pneumonia management tactics promotes market growth.
Leading Players in the Global Pneumonia Therapeutics Market
- AstraZeneca (U.K.)
- Lilly (U.S.)
- Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Hikma Pharmaceuticals PLC (U.K.)
- Cipla Inc. (India)
Global Pneumonia Therapeutics Market Recent Developments
- In May, 2024 Zai Lab and Innoviva Specialty Therapeutics received NMPA approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) in China treating hospital-acquired and ventilator-associated pneumonia caused by the Acinetobacter Baumannii-Calcoaceticus Complex.
- In Spetember, 2023, Phaxiam Therapeutics SA launched a new preclinical research program aimed at Klebsiella pneumoniae, a bacteria that causes serious infections and is known for its great resistance to antibiotics.
- In May, 2023 the U.S. Food and Drug Administration has authorized a new drug Xacduro produced by Innoviva Specialty Therapeutics, which is used to treat hospital-acquired pneumonia caused by a difficult-to-treat bacteria.
- In November, 2023 The COMBINE (Collaboration for the Prevention and Treatment of MDR Bacterial Infections) initiative of the Innovative Medicines Initiative is creating a standardized in vivo pneumonia model to test small-molecule antibiotics.
SKU-